Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
ConclusionsDespite consistent guideline recommendations for cytoreductive therapy in patients with high-risk PV, this analysis revealed that only a minority of these patients received cytoreductive medication. A notable proportion of high-risk patients with PV would likely benefit from a revised treatment plan that aligns with current guidelines.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
More News: Aspirin | Cancer & Oncology | Cardiology | Cardiovascular | Congestive Heart Failure | Databases & Libraries | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Hematology | Hypertension | Phlebotomy | Study | USA Health